The Pharmacological Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has made new recommendations about the use of ivabradine (Procorolan; Servier). A review of the evidence found that, out of patients with coronary artery disease, a subgroup with symptomatic angina treated with ivabridine were at higher risk of cardiovascular death or non-fatal heart attack. Following this review, PRAC has stated that the medicine should only be used for symptom relief of angina, that patients should be monitored for atrial fibrillation, and that the dose should not exceed 7.5mg twice daily and should start at 5mg twice daily, alongside other recommendations. More information can be found on the EMA website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067138